CRISPR Therapeutics Aktie
56,50
EUR
-1,50
EUR
-2,59
%
66,27
USD
+0,16
USD
+0,24
%
Werbung
CRISPR Therapeutics Aktie Analyse
26.07.19 | CRISPR Therapeutics Buy | Canaccord Adams | |
30.11.18 | CRISPR Therapeutics Buy | Needham & Company, LLC | |
15.05.18 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
28.03.17 | CRISPR Therapeutics Buy | Chardan Capital Markets | |
14.11.16 | CRISPR Therapeutics overweight | Barclays Capital |
Werbung
Werbung